New targeted radiation treatment delivered via PRRT
New targeted radiation treatment delivered via PRRT

Targeted Radiation Therapy Approved by
Food and Drug Administration

The U.S. Food and Drug Administration (FDA) approved Lutetium 177 DOTA-TATE (Lu 177), a type of Peptide Receptor Radionuclide Therapy (PRRT), for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut tumors in adults. (MORE)

Amino Acid Beverage Reduces Diarrhea in Pilot Study

Lowell Anthony, MD, University of Kentucky, presented a poster at the January 2018 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology (ASCO), on an ongoing Phase II clinical trial of a commercially available amino acid medical beverage, which showed a reduction in bowel movements in five out of eight patients studied. The product includes electrolytes and amino acids to support gut health and improve hydration. (MORE) 

Clinical Trials Overview 

From Indy Patient Conference

Clinical trials offer eligible patients access to investigational tests and treatments. Learn about different types and phases of clinical trials, plus find out about the latest studies underway for NET cancers in this talk by  Bhavana Konda, MD, and Allan Espinosa, MD, The James, Ohio State University Comprehensive Cancer Center. (MORE) 
Caring and Sharing

Giving Expands Pilot Projects

Our successful year-end appeal will help us fund additional pilot research projects in 2018. Watch for our official grant awards announcement in the March e-newsletter on the innovative projects your generous gifts helped make happen. Thank you.

Tax Season for Donors

As a result of changes to the tax code, fewer Americans will itemize their taxes in the future. Get in touch with your tax professional early to discuss these changes. When you sit down with your tax preparer, talk about your giving plans for 2018. You may want to explore new options to maximize the tax benefit of charitable gifts. NETRF welcomes gifts of appreciated securities, 401Ks, donor-advised funds, trusts, or bequests. For information, please contact Elyse Gellerman, NETRF CEO, at (617) 946-1783.
Education and Advocacy

Mark Your Calendars

Join the NETRF and University of Pennsylvania Abramson Cancer Center as we host the 7th Focus on Neuroendocrine Tumor Patient and Caregiver Conference on Friday, April 13 in Philadelphia, Pennsylvania. NETRF Board of Scientific Advisors member, Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center,  will give the keynote presentation on theranostics for NETs. Watch for details and please plan to join us. 

Upcoming Awareness Days

November 4 is #WorldCancerDay and February 28 is #RareDiseaseDay (#ShowYourRare).
Join us in raising awareness about NET Cancer. Watch NETRF’s Facebook and Twitter accounts for statistics and information you can share with your friends and family. Action and advocacy help us work towards reducing delays in diagnosis, increasing research, and expanding treatment options.  

Tumor Tissue Donation

Do you have a surgery or biopsy planned? NETRF is partnering with to help patients direct their excess cancer tissue samples to research projects, which helps advance our understanding of rare diseases. offers an electronic consent form where you can learn about research projects, find contact information, and provide consent if you wish to contribute. (MORE) 
We are pleased to announce that this eUpdate 
is sponsored by Novartis Pharmaceutical Corporation.
Doctor Database   Patient Groups
Newly Diagnosed   About NETs
Facebook Twitter
Contact Us

NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston, MA 02116

(617) 946-1780 |
The mission of the Neuroendocrine Tumor Research Foundation is to fund research to discover cures and more effective treatments for carcinoid, pancreatic, and related neuroendocrine cancers.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. To learn more,
view our Audited Financial Statements and IRS Form 990.
powered by emma
Subscribe to our email list.